Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 5Lymphoid 5Other hematologic neoplasm 3Myeloid 2Classical hematology 2Sarcoma 1Gynecologic 1

Conditions

Sarcoma 436Osteosarcoma 132Sarcoma, Ewing 89Melanoma 80Rhabdomyosarcoma 77Neoplasms 71Gastrointestinal Stromal Tumors 63Neuroblastoma 62Bone Neoplasms 62Breast Neoplasms 61Ovarian Neoplasms 60Colorectal Neoplasms 60Glioblastoma 55Neoplasm Metastasis 52Liposarcoma 52Dendritic Cell Sarcoma, Interdigitating 45Carcinoma, Non-Small-Cell Lung 43Leiomyosarcoma 42Gliosarcoma 42Stomach Neoplasms 41Pancreatic Neoplasms 41Lymphoma 36Uterine Cervical Neoplasms 35Sarcoma, Synovial 35Carcinoma, Renal Cell 35Rhabdoid Tumor 34Neurofibrosarcoma 34Lung Neoplasms 34Glioma 34Sarcoma, Kaposi 33

Interventions

ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemostatic Disorders × Sarcoma × 1 year × Clear all
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡